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Abstract 16 
Canine pyoderma remains one of the main presentations in small animal practice and 17 
frequently leads to prescribing of systemic antimicrobials. A good foundation knowledge on 18 
pyoderma was established during the 1970s and 1980s when treatment of infection provided little 19 
challenge. However, our ability to treat canine pyoderma effectively is now limited substantially by 20 
the emergence of multidrug-resistant, methicillin-resistant staphylococci (MRS) and in some 21 
countries, by restrictions in antimicrobial prescribing for pets. The threat from rising antimicrobial 22 
resistance and the zoonotic potential of MRS add a new dimension of public health implications to 23 
the management of canine pyoderma and urge a revisit and the search for new best management 24 
strategies. This narrative review focusses on the impact of MRS on how we manage canine 25 
pyoderma, and how traditional treatment recommendations need to be updated in the interest of 26 
good antimicrobial stewardship. Background information on clinical characteristics, pathogens and 27 
appropriate clinical and microbiological diagnostic techniques are briefly reviewed in so far as they 28 
can support early identification of multidrug-resistant pathogens. We examine the potential of new 29 
approaches for the control and treatment of bacterial skin infections and highlight the role of owner 30 
education and hygiene. Pyoderma patients offer great opportunities for good antimicrobial 31 
stewardship by making use of the unique accessibility of the skin through cytology, bacterial culture 32 
and topical therapy. For long-term success and to limit the spread of multidrug-resistance, we need 33 
to focus on identification and correction of underlying diseases that trigger pyoderma in order to 34 
avoid repeated treatment. 35 
 36 
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Introduction 39 
Although good prevalence data for canine pyoderma are lacking, bacterial skin infections 40 
were the second most frequent cause for presentation to first opinion practice in a UK survey on 41 
canine skin problems (Hill et al., 2006). Rarely life-threatening, pyoderma substantially contributes 42 
to canine morbidity through associated pruritus or pain, and potentially widespread and severe 43 
inflammatory changes. Because pyoderma is always secondary to underlying disease, unless this is 44 
corrected, recurrence is likely requiring repeated therapy, and causing frustration and continuing 45 
expense. 46 
 47 
Indeed, pyoderma is one of the main presentations leading to antimicrobial prescription in 48 
small animal practice (Hughes et al., 2012). A recent UK first opinion practice survey showed that 49 
92% of 683 dogs with pyoderma, either suspected or confirmed, received systemic antibacterial 50 
therapy (Summers et al., 2014). With continuing emergence of methicillin-resistant staphylococci, 51 
mainly S. aureus (MRSA) and S. pseudintermedius (MRSP), it is necessary to reduce antimicrobial 52 
use as a principal driver of multidrug-resistance (MDR) and pyoderma provides excellent 53 
opportunities for good antimicrobial stewardship. 54 
 55 
In this narrative review, we focus on how the emergence of MRSP, MRSA and other 56 
MDR zoonotic pathogens has changed our approach to the management of canine pyoderma, 57 
and on how traditional treatment recommendations need to be adapted to deal with this increasing 58 
threat to antimicrobial effectiveness and to public health. 59 
 60 
Foundation knowledge and clinical disease 61 
Aetiology and pathogenesis 62 
Since publication of the first comprehensive veterinary dermatology text books in the 1960s 63 
(Muller and Kirk, 1969), pyoderma has consistently featured as one of the major diseases affecting 64 
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canine skin. It has been suggested that this is partly a consequence of the comparatively thin and 65 
compact canine stratum corneum, of the paucity of intracellular emulsion in canine epidermis and 66 
of the lack of a sebum plug in the canine hair follicle (Lloyd and Garthwaite, 1982; Mason and 67 
Lloyd, 1993). 68 
 69 
The critical question of why pyoderma, particularly superficial pyoderma, develops and 70 
frequently recurs, is still incompletely understood. The major role of primary underlying disease in 71 
its aetiology is supported by the observation that the predominant staphylococcal pathogens are 72 
colonisers of healthy dogs and that most staphylococcal skin infections involve ‘endogenous’ 73 
strains, i.e. isolates genetically identical to those of the patient’s healthy cutaneous and mucosal 74 
microflora (van Eiff et al., 2001; Pinchbeck et al., 2006 & 2007). 75 
 76 
Common underlying triggers such as ectoparasite infestations, allergic skin diseases and 77 
endocrinopathies have long been associated with pyoderma, with allergic disease likely the main 78 
driver for recurrent forms (Mason and Lloyd, 1989; Colombo et al., 2007; Bloom, 2014). More 79 
specific concepts of quorum sensing, of a minimum infective dose and most recently findings from 80 
microbiome studies showing significant changes in diversity and composition during atopic 81 
dermatitis have provided new insights on why infection with opportunistic bacteria may develop in 82 
skin (Lloyd, 2014; Pierezan et al., 2016; Rodrigues Hoffman et al., 2017). Immunological defects in 83 
innate and adaptive immunity were identified in deep pyoderma of German shepherd dogs 84 
presenting with widespread, highly inflammatory infections during the 1980s and 1990s (e.g. 85 
Wisselink et al., 1988; Chabanne et al., 1995; Shearer and Day, 1997) but could not be conclusively 86 
linked to the breed or the occurrence of pyoderma (Rosser, 2006). Fortunately, this devastating 87 
disease now seems to be rare, possibly following targeted breeding. 88 
 89 
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The gaps in our understanding remain frustrating but it is important to remember that, when 90 
underlying causes are not identified, use of the term “idiopathic pyoderma” does not represent a 91 
diagnosis. In such cases diagnostic investigations need to be continued as failure to eliminate or 92 
control underlying disease or predisposing factors will lead to recurrence. 93 
 94 
Classification and diagnosis of pyoderma 95 
With its secondary aetiology and the need for responsible use of antimicrobials in mind, a 96 
diagnosis should always include i) recognition of suggestive skin lesions and likely depth of 97 
infection, ii) confirmation of bacterial infection through cytology and iii) identification of 98 
underlying primary disease. 99 
 100 
Despite its prevalence, canine pyoderma is often misdiagnosed (Gortel, 2013) leading to 101 
inappropriate treatment. Recognition of suggestive skin lesions and their distribution is essential 102 
and requires careful inspection of the skin. Since the number of ways skin can react to insult is 103 
limited, classifications have been proposed to facilitate morphological diagnosis. The most widely 104 
used is based on depth of infection and distinguishes surface, superficial and deep pyoderma, all 105 
three associated with typical clinical presentations (Ihrke, 1987; White and Ihrke, 1987) (Fig. 1). 106 
 107 
Surface pyoderma remains the least understood group. It includes frequently seen 108 
presentations such as acute moist dermatitis (“hot spots”, pyotraumatic dermatitis), fold pyoderma 109 
(intertrigo), and the more recently described microbial/bacterial overgrowth syndrome in which 110 
erythema is the only clinical sign but large numbers of bacteria on the inflamed skin can be 111 
demonstrated by cytology (Pin et al., 2006). Here, excessive multiplication of bacteria is confined 112 
to the skin surface and is seen as a minor player in the pathogenesis, triggered by a dominant 113 
inflammatory cause. 114 
 115 
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Superficial pyoderma involves invasion of the epidermis. Bacterial folliculitis extends into 116 
the follicular ostium and epidermal tissue and is likely the most frequent pyoderma type in dogs. It 117 
presents with papules, pustules and epidermal collarettes, typically on the ventral abdomen and 118 
medial thighs or on the trunk and often associated with areas of alopecia and varying degrees of 119 
pruritus; its interfollicular form (impetigo) occurs mostly in puppies. Coat type and immune-status 120 
can also influence clinical appearance as in the moth-eaten appearance of superficial pyoderma in 121 
short-coated breeds or in the large lesions (collarettes, pustules) associated with bullous impetigo or 122 
superficial spreading pyoderma in immune-compromised dogs (Bloom, 2014; Beco et al., 2013a). 123 
Mucocutaneous pyoderma is a disease of unknown aetiology. It primarily affects lips and perioral 124 
skin, with swelling, erythema and crusting which may lead to fissuring and erosion. It often 125 
responds slowly to therapy and can be confused with immune-mediated disease. 126 
 127 
Deep pyoderma is less common but more serious, as its expansion into the dermis and 128 
proximity to blood vessels increases the risk of haematogenous spread and bacteraemia. It can be 129 
seen with any underlying trigger or acquired immuno-deficiency but is commonly associated with 130 
demodicosis (Kuznetsova et al., 2012; Mueller et al., 2012). Lesions include draining sinuses, 131 
fistulae, haemorrhagic crusts, nodules and varying degrees of erythema and swelling; pain is not 132 
infrequent. Common localised forms of deep pyoderma affect the head (chin acne, muzzle 133 
folliculitis and furunculosis) or limbs (interdigital nodules, callus pyoderma, acral lick granuloma). 134 
Nodular lesions quite often involve bacteria other than staphylococci and need to be differentiated 135 
from non-bacterial infected granulomas, sterile granulomatous disease, neoplasia and foreign body 136 
reactions by biopsy, special stains, macerated tissue culture and sometimes molecular techniques. 137 
 138 
For initial diagnosis, cytology from slide or tape impressions, a frequent requirement of 139 
antimicrobial stewardship guidelines prior to antimicrobial prescription (e.g. BVA, 2015), is 140 
recommended to confirm bacterial involvement. Cytology of superficial pyoderma lesions is 141 
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reported to have 93% diagnostic sensitivity, based on presence of neutrophils and intracellular cocci 142 
(Udenberg et al., 2014) but, despite being rapid and inexpensive (Curtis, 2001), remains underused 143 
in general practice (Hill et al., 2006). 144 
 145 
Bacterial culture, on the other hand, is of limited value in the initial diagnosis of pyoderma. 146 
It is likely to yield staphylococci from infected and non-infected skin (Doelle et al., 2015), and can 147 
therefore not distinguish infected from colonised skin. However, bacterial culture and antimicrobial 148 
susceptibility testing are essential for selection of systemic therapy after a diagnosis has been 149 
established. It is of note that sampling can be challenging, particularly in deep pyoderma for which 150 
surface swabs have been shown to predict relevant pathogens from deep infection in only about 151 
30% of cases (Shumaker et al., 2008) and submission of tissue (in saline, not formalin) obtained 152 
through biopsy is preferred. 153 
 154 
Pathogens 155 
The predominant role of coagulase-positive staphylococci has been long recognised (Ihrke, 156 
1987). Originally all such infections were ascribed to S. aureus, but refinement of microbiological 157 
techniques allowed new species including S. intermedius and S. pseudintermedius to be described 158 
(Table 1). S. pseudintermedius is recognised to be most commonly involved, particularly in 159 
superficial pyoderma (Medleau et al., 1986; Shumaker et al., 2008). Other staphylococci, including 160 
S. aureus, S. schleiferi and S. hyicus may be involved in up to 10% of cases. 161 
 162 
Staphylococci have an array of potential virulence factors but despite detailed investigation 163 
significant associations between specific virulence genes and disease have not yet been identified, 164 
shifting attention again to host factors that may facilitate infection (Bannoehr et al., 2012; Tanabe et 165 
al., 2013; Couto et al., 2015). However, biofilm production, which can promote resistance to host 166 
defence mechanisms and greatly enhance antimicrobial resistance, has been confirmed in many 167 
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isolates of S. pseudintermedius and other veterinary staphylococci (Götz, 2002; Hall-Stoodley et al., 168 
2004). 169 
 170 
Many other bacterial pathogens, including Pseudomonas aeruginosa, Proteus spp., 171 
streptococci, Burkholderia spp. and Escherichia coli may be difficult to distinguish clinically 172 
(Rantala et al., 2004; Hillier et al., 2006; Cain et al., 2015; Tham et al., 2016). Isolation of 173 
coagulase-negative staphylococci, such as S. lugdunensis and S. schleiferi subsp. schleiferi, and of 174 
Macrococcus spp., can also cause confusion in laboratories that are looking for coagulase-positive 175 
bacteria (Cain et al., 2011; Gobeli Brawand et al., 2016; Cotting et al., 2017). Surprisingly, the idea 176 
that coagulase-negative staphylococci are non-pathogenic persists even though they are the most 177 
common cause of nosocomial bacteraemia in human hospitals (von Eiff et al., 2002; Becker et al., 178 
2014) and are increasingly reported in animal infections (e.g. Rook et al., 2012; Frank et al., 2008; 179 
Davis et al., 2013; Kern and Perreten, 2013; Ruzauskas et al., 2014). 180 
 181 
Emergence of multidrug-resistance 182 
Resistance to antimicrobials within bacterial populations is an ancient phenomenon, vital for 183 
bacterial survival (D’Costa et al., 2011; Perron et al., 2015). However, the accumulation of multiple 184 
resistance genes in bacterial pathogens, driven by overuse of antimicrobial drugs, has become a 185 
chilling threat to human and animal health (Gossens et al., 2005; Costelloe et al., 2010). 186 
 187 
First concerns about MDR in canine pyoderma emerged twenty years ago when MRSA 188 
became recognised in sporadic skin and wound infections; later, the more epidemic spread of 189 
MRSP overtook it and now presents major challenges to our management of canine pyoderma. In 190 
addition, all key multidrug-resistant pathogens of relevance in human medicine, such as 191 
Enterococcus faecium, Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa and 192 
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Enterobacter spp. (Boucher et al., 2009), are now recognised to be associated with infection in pets 193 
(Grobbel et al. 2007; Kuzi et al., 2016; Abdel-Moein et al., 2017). 194 
 195 
Meticillin-resistance in staphylococci 196 
Although methicillin is no longer available for clinical use, it still serves as a marker for 197 
broad resistance to all β-lactams (excepting some of the latest anti-staphylococcal molecules) and as 198 
an indicator of likely nosocomial epidemiology and additional multidrug-resistance. The genetic 199 
basis underpinning methicillin-resistance is the presence of the mecA gene held on a large mobile 200 
genetic element, the staphylococcal cassette chromosome (SCC). This is similar in all staphylococci 201 
and has been extensively studied for MRSA (Lindsay and Holden, 2006). 202 
 203 
Since the first identification of MRSA from pets, isolates from pets and humans have been 204 
found genetically identical, providing indirect but good evidence that transmission between these 205 
hosts can occur in both directions (reviewed by McCarthy et al., 2012). MRSA was the first 206 
multidrug-resistant Staphylococcus to receive attention in animals when pets contaminated by 207 
human MRSA patients were shown to be involved in perpetuating human infection or recurrent 208 
outbreaks (Scott et al., 1988; Manian, 2003). Since then, sporadic infections, case series and 209 
outbreaks have been reported, typically involving skin and wound infections in dogs (Tomlin et al., 210 
1999; Paterson et al., 2015; Morris et al., 2017). Most reports are from countries with a high MRSA 211 
prevalence in human hospitals, indicating a spill-over from humans; epidemic spread beyond clinic 212 
or kennel outbreaks has not been reported. Fortunately, the prognosis in such infections can be 213 
considered good, depending on underlying causes, as the great majority of these human hospital-214 
associated MRSA remain susceptible to tetracyclines and potentiated sulphonamides and around 215 
50% to clindamycin. A less predictable prognosis needs to be considered for rare infections 216 
involving MRSA from human lineages that carry toxins such as Panton-Valentine-leucocidin 217 
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(Rankin et al., 2005; van Duikeren et al., 2005) and those associated with livestock-associated 218 
MRSA (Gómez-Sanz et al., 2013). 219 
 220 
A much greater veterinary challenge is the emergence in dogs of MRSP, associated with 221 
even broader drug-resistance. Whole genome sequencing shows that only three genetic steps 222 
(acquisition of mecA on a SCC, acquisition of a large transposon (Tn5405-like element) carrying up 223 
to five resistance genes and genome point mutations for fluoroquinolone and sulphonamide 224 
resistance) are required for its rapid evolution to MDR, emphasising the important role of selection 225 
pressure (Loeffler et al., 2007; Perreten et al., 2010; Detwiler et al., 2014; McCarthy et al., 2015). 226 
 227 
First reported from dogs in North America in the late 1990s (then MRSI), MRSP accounted 228 
for over 30% of staphylococcal isolates from American dogs within less than ten years (Gortel et 229 
al.,1999; Morris et al., 2006; Jones et al., 2007) and is now identified worldwide. An even higher 230 
prevalence was recently reported from China and Japan with nearly 50% and 70%, respectively 231 
(Feng et al., 2012; Kasai et al., 2016). In the UK, where MRSP was first recognised in 2009, the 232 
burden seems relatively low with rates below 5% of clinical S. pseudintermedius laboratory 233 
submissions reported in 2015 (Maluping et al., 2014; Beever et al., 2015). In contrast, studies from 234 
continental Europe, where MRSP had been identified three years earlier, prevalence was soon 235 
reported around 30% (Loeffler et al., 2007; DeLucia et al., 2011). 236 
 237 
Substantial percentages of methicillin-resistance have also been reported in coagulase-238 
variable S. schleiferi (subspecies schleiferi and subspecies coagulans), some from pyoderma but 239 
most from otitis (Cain et al., 2011). 240 
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 241 
Clinical implications and early identification 242 
Clinically, MRS infections in animals are no different from infections involving less 243 
resistant staphylococci (Fig. 1) (Morris et al., 2017). In fact, early case-control studies showed that 244 
clinical outcome was no worse for MRSA and MRSP infections in pets compared to those 245 
involving their susceptible counterparts, provided that a safe antibacterial treatment option was 246 
available (Weese et al., 2012; Lehner et al., 2014). Finding treatment options may be troublesome 247 
and treatment has been shown to take longer than with susceptible staphylococci (Bryan et al., 248 
2012). However, the bigger concern with MRS pyoderma is its potential for spreading these 249 
zoonotic, multidrug-resistant pathogens to other animals and people, and into the environment. For 250 
MRSP, the risk of zoonotic transmission is generally considered low as low carriage rates of S. 251 
(pseud)intermedius have been found in people regularly exposed to dogs (Havey et al. 1994; 252 
Goodacre et al., 1997; Han et al., 2016). As for all staphylococci though, the risk is increased for 253 
immune-compromised people and individual cases of zoonotic MRSP infection have been reported 254 
(Stegman et al., 2010; Somayaji et al., 2016; Lozano et al., 2017). 255 
 256 
Transmission of staphylococci is supported by their ability to survive on dry surfaces and at 257 
healthy skin and mucosal carriage sites for many months, equipping them for nosocomial spread 258 
(Wagenvoort et al., 2000; Windahl et al. 2016). Early identification of MRS by clinicians is 259 
therefore crucial to limit outbreaks but it relies on awareness of risk factors. Risk factors for 260 
multidrug-resistant infection in human medicine are well documented and include frequent 261 
hospitalisation, length of stay in hospitals, surgical interventions and repeated antimicrobial therapy 262 
(Sadfar and Maki, 2002). Unsurprisingly, the same risk factors have been identified for MRSA and 263 
MRSP infections in dogs (Soares-Magalhães et al., 2010; Baker et al., 2012; Lehner et al. 2014; 264 
Weese et al., 2012). 265 
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 266 
New focus on laboratory identification 267 
Before the emergence of MRS, species identity of a coagulase-positive Staphylococcus was 268 
probably of little importance to most clinicians. When MRS are involved, accurate differentiation 269 
between MRSA and MRSP is critical for further management as important epidemiological 270 
differences exist. Isolation of MRSA from a dog will prompt a focus on human health concerns and 271 
the need to inform the owner’s human physician. In contrast, isolation of the dog-adapted MRSP 272 
should initiate all appropriate infection control measures recommended for veterinary nosocomial 273 
pathogens and advice on limiting contagion to other animals, while only a lower zoonotic risk needs 274 
to be considered (Morris et al., 2017). 275 
 276 
Unfortunately, it has also become clear that identification through phenotypic assessment 277 
alone is more difficult than text books suggest as subtle morphological and biochemical variation 278 
occurs within bacterial populations (Pottumarthy et al., 2004; Sasaki et al., 2007; Geraghty et al., 279 
2013; Bond and Loeffler, 2012). Similarly, recognition and accurate identification of coagulase-280 
negative staphylococci is important as their pathogenic potential is increasingly recognised; 281 
reporting such isolates as ‘consistent with microflora organisms’ is no longer sufficient. Semi-282 
automated and automated laboratory procedures help with speciation but are commonly set up for 283 
human bacterial pathogens and may lack precision for veterinary isolates. Currently, best accuracy 284 
in a diagnostic setting is achieved by Matrix Assisted Laser Desorption/Ionisation Time of Flight 285 
Mass Spectrometry (MALDI-TOF) which has been validated for many veterinary pathogens 286 
including the very similar SIG species (Decristophoris et al., 2011; Sauget et al., 2016; Somayaji et 287 
al., 2016). 288 
 289 
Susceptibility testing is most often done by traditional disk diffusion with clinical 290 
breakpoints guiding predictions on clinical efficacy. Dilution testing and minimum inhibitory 291 
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concentrations (MICs) were rarely needed for the management of skin infections in the past but will 292 
be helpful in multidrug-resistant infections when a borderline MIC may still be overcome with high 293 
doses of an authorised antimicrobial rather than choosing a less safe drug, or when calculating 294 
dosages for treatment with an unauthorised agent. Resistance testing against methicillin, nowadays 295 
replaced by oxacillin, can also been misleading since mecA-independent mechanisms (other mec 296 
types, hyper-penicillinase producers, incomplete expression) can lead to inconsistent results (Morris 297 
et al., 2017). Confirmation of phenotypic methicillin-resistance by additional tests (molecular for 298 
mecA or by agglutination tests detecting an altered penicillin-binding protein encoded by mec) is 299 
desirable before MRS management decisions are initiated (Becker et al., 2014b). 300 
 301 
Management of canine pyoderma 302 
In the past, treatment of canine pyoderma was rarely challenging as S. pseudintermedius 303 
(formerly S. intermedius) was widely susceptible and broad-spectrum antibacterial agents such as 304 
cephalexin, potentiated amoxicillin and enrofloxacin became licensed for use in dogs during the 305 
1970s and 1980s, all with an indication for skin infection (Medleau et al., 1986; Kruse et al., 1996; 306 
Lloyd et al., 1996; Pellerin et al., 1998; Normand et al., 2000). It was already recognised that 307 
isolates from animals that had repeatedly received antimicrobials were likely to show more 308 
resistance (Noble and Kent, 1992; Holm et al., 2002) but empirical selection of drugs for systemic 309 
treatment of pyoderma was nearly always successful. This situation began to change around 20 310 
years ago when methicillin-resistant, multidrug-resistant staphylococci were recognised amongst 311 
canine clinical isolates and, in the UK, there is now evidence that resistance to most antimicrobial 312 
classes is gradually increasing (Beever et al., 2015). Based on recent data for small animal 313 
pathogens, this trend of increasing AMR is likely to continue worldwide (Ludwig et al., 2016). 314 
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Topical therapy 316 
Topical antibacterial therapy has always been advised for surface infections and, in 317 
combination with systemic therapy, for superficial and deep pyoderma (Ihrke, 1987; Curtis, 1998 & 318 
1999). However, newer studies have provided good evidence that topical therapy can be effective as 319 
sole antibacterial treatment in superficial pyoderma, including cases with MRS (Murayama et al., 320 
2010; Loeffler et al., 2011; Borio et al., 2015). In situations where pet and owner can be expected to 321 
be compliant and where clinicians are prepared to convince owners of its merits, topical treatment 322 
can help to reduce overall antimicrobial prescription. 323 
 324 
A wide range of different formulations, such as shampoos, creams, gels and ointments, and 325 
more recently foams, is marketed for dogs and includes a variety of antibacterial agents; this can be 326 
confusing. A systematic review of topical therapy for canine bacterial skin infections concluded that 327 
while evidence from randomised controlled trials was sparse, good evidence supported the use of 328 
shampoos containing 2-3% chlorhexidine and, to a lesser extent, benzoyl peroxide (Mueller et al., 329 
2012) and these continue to be the mainstay of topical therapy, at least for widespread disease. 330 
Localised infections can also be treated with creams or gels containing antibiotics such as fusidic 331 
acid, authorised for use in dogs in European countries and in Canada, or mupirocin ointment 332 
authorised in the USA for dogs but reserved for use in human medicine in most of Europe (Cobb et 333 
al., 2005; BNF, 2017). 334 
 335 
While concern over resistance to topically used antibacterial agents exists, clinical treatment 336 
failure of topical anti-staphylococcal therapy has not been conclusively reported, to the authors’ 337 
knowledge; MICs for staphylococci from animals have been consistently low and are likely to be 338 
substantially exceeded by achievable topical drug concentrations (Loeffler et al. 2008; Valentine et 339 
al., 2012; Clark et al., 2015). However, continual monitoring of resistance and clinical efficacy, 340 
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further evaluation of alternatives such as hypochlorite (bleach), Manuka honey, of potentially 341 
synergistic combinations and of anti-biofilm products will be critical (Walker et al., 2016). 342 
 343 
Combination of topical treatment with systemic treatment is recommended whenever 344 
possible to potentially reduce the duration of systemic therapy, and in MRS infections, to reduce 345 
environmental contamination and risk of transmission to other hosts. 346 
 347 
Systemic therapy 348 
Systemic therapy, required for deep pyoderma and for widespread or severe superficial 349 
infections, should follow the concept of ‘as little as possible but as much as necessary’ (RUMA 350 
2009). Efficacy depends predominantly on bacterial susceptibility but will also be determined by 351 
correct drug administration, appropriate dosing, owner compliance and clinical variables such as 352 
severity of infection and causative and concurrent diseases. Surprisingly, despite their universal use, 353 
evidence on efficacy of systemic antimicrobial agents is sparse as only few adequate studies 354 
documenting outcome exist (Summers et al., 2012). 355 
 356 
While bacterial culture and susceptibility testing would be desirable for every patient and is 357 
never contraindicated in pyoderma, realistically, cost, perceived delay of effective treatment and 358 
clinical time pressure often motivate empirical drug selection. In countries with low MRS 359 
prevalence, empirical selection may still be effective for most superficial pyodermas. In high-MRS 360 
prevalence countries, this can no longer be considered reliable or cost-effective. Indeed, repeated 361 
testing may be required as antimicrobial therapy has been shown to promote acquisition of MRSP 362 
in dogs not previously MRSP-positive (Beck et al., 2012). Recent pyoderma guidelines further 363 
specify that culture and susceptibility testing is essential in all dogs with deep pyoderma, those with 364 
a history of MRS or with owners reporting MRS in themselves, and in dogs where appropriate 365 
empirical antibiosis has been ineffective. (Beco et al., 2013b; Hillier et al., 2014) 366 
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 367 
When prescribing antimicrobial drugs for dogs, it is important to remember that most are 368 
also used in human medicine, either as identical or related molecules, and that key agents for canine 369 
pyoderma are listed by the WHO as ‘critically important antimicrobials’ or ‘highly important for 370 
human medicine’ (WHO, 2011). 371 
 372 
For non-MRSP pyoderma, most antimicrobials authorised for use in dogs would be effective 373 
if prescribed appropriately. Treatment recommendations have recently been detailed in two free 374 
access publications, one on pyoderma by a group of veterinary dermatologists (Beco et al., 2013b), 375 
the other on superficial bacterial folliculitis by the International Society for Companion Animal 376 
Infectious Disease (ISCAID)(Hillier et al., 2014). Briefly, antimicrobial drugs can be classified into 377 
first and second tier/line drugs, depending on the likelihood that they will be effective against 378 
staphylococci and their spectrum of activity against Gram-negative pathogens. First-tier drugs, such 379 
as clindamycin, first-generation cephalosporins, amoxicillin-clavulanate or potentiated 380 
sulphonamides may be chosen empirically in areas with a low prevalence of MRS. Clindamycin, 381 
an antimicrobial with good efficacy against most staphylococci, can be considered as a 382 
responsible treatment choice due to its relatively narrow spectrum of activity. However, 383 
clinicians need to be familiar with their local S. pseudintermedius resistance pattern as 384 
differences in resistance have been recognised between countries and between isolates from 385 
first-time pyoderma versus those from recurrent pyoderma (Holm et al., 2002; Beever et al., 386 
2015; Larsen et al., 2015). Treatment with second-tier agents, such as for example 387 
fluoroquinolones, should always be based on bacterial culture and susceptibility results. Readers are 388 




In MRS pyoderma, drugs predicted to be effective by in vitro testing are selected based on 392 
national licensing rules, their clinical and safety characteristics, dosing practicalities and cost, with 393 
no single drug shown to be better than another. Information specifically on MRS treatment is 394 
detailed in recently published open access Clinical Consensus Guidelines on MRS infections 395 
(Morris et al., 2017). Specifically on the interpretation of resistance testing, the guidelines point out 396 
that no representatives of -lactam antibiotics should be used for MRS infections even if testing 397 
indicates susceptibility for individual agents of this class, that testing for inducible resistance to 398 
clindamycin is recommended for MRS to avoid treatment failure during therapy, that extrapolation 399 
of results for one type of tetracycline to another can be unreliable as resistance is mediated by a 400 
number of different genes and that resistance to one fluoroquinolone is likely to indicate resistance 401 
to others in MRSP; MIC determination may then help to inform treatment decisions (Kizerwetter-402 
Świda et al., 2016). 403 
 404 
When no susceptibilities to clinically relevant and authorised antimicrobials are reported, 405 
extended testing is required. Amikacin, rifampicin and chloramphenicol are most frequently 406 
mentioned for such infections (Frank and Loeffler, 2012; Papich, 2012) but their use should be 407 
preceded by appropriate dose calculations and toxicity monitoring, requires detailed owner 408 
education and compliance, and should include advice on infection control measures to limit spread 409 
(Morris et al., 2017). In the authors’ opinion, glycopeptides, linezolid and potentially new 410 
compounds should be strictly reserved for use in humans. Some institutions may consider these 411 
under restriction-of-use protocols but this should rarely be necessary for pyoderma (Weese, 2008). 412 
 413 
Recommendations on how long to treat pyoderma for remain controversial. Traditional 414 
advice, based on clinical expertise is three weeks or one week beyond clinical cure for superficial 415 
pyoderma, and four to eight weeks or two weeks beyond clinical cure for deep pyoderma (Ihrke, 416 
1987). In addition, many datasheets now recommend several weeks of therapy. In human medicine, 417 
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antibiotic courses are typically shorter but recently, even the advice to patients to complete a course 418 
after clinical signs have resolved has been questioned (Llewelyn et al., 2017). In the absence of 419 
better data, it is prudent to follow advice from ISCAID and adhere to the traditional 420 
recommendations but where shorter treatment is prescribed, plans for close monitoring of progress 421 
by veterinarian rather than owner should be made (Hillier et al., 2014). In addition, resolution of 422 
clinical signs will not signal the end of case management for MRS pyoderma as dogs can become 423 
carriers and carry the risk of contagion, including zoonotic transmission, and of self-re-infection. 424 
 425 
Correction of primary triggers, follow-up and prevention 426 
After resolution of any type of pyoderma, prevention of recurrence is very important as 427 
multidrug-resistance may develop with repeated systemic treatment. Such prevention will depend 428 
on elimination or suppression of underlying triggers. A diagnosis of these triggers may not be a 429 
priority to owners compared to the urgency of resolving the pyoderma, and will present an extra 430 
challenge to communication during busy consultations. Most problematic, in the authors’ 431 
experience, are those dogs that in the absence of pyoderma (i.e. when infection has been resolved) 432 
present either with no clinical signs suggestive of underlying triggers or with signs compatible with 433 
very mild allergic skin disease. In those cases, provided history and signalment are in line with 434 
allergic skin disease, empirical treatment with anti-inflammatory medication may help to prevent 435 
flares of bacterial infection. If successful, this approach can subsequently be optimised by further 436 
investigations into allergic skin disease (Olivry et al., 2015). 437 
 438 
Importantly for MRS infections, once infection has resolved, animals will continue to 439 
harbour staphylococci on healthy skin and mucosae. For MRSP, a bacterium well adapted to dogs 440 
(Simou et al., 2005), carriage has been shown to continue for up to 11 months after infection has 441 
resolved (Windahl et al., 2012). Carriage and environmental contamination and the risk of 442 
subsequent self-re-infection have long been suspected as major contributors to the successful spread 443 
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of human MRSA and a similar epidemiology is suspected for MRSP in veterinary settings (Beck et 444 
al., 2012; Morris et al., 2017). 445 
 446 
New approaches 447 
The growing problem of antimicrobial resistance and the lack of effective, new conventional 448 
antimicrobial drugs has promoted the development of different approaches to prevention and 449 
control of bacterial infections (Lloyd, 2012; Vale et al., 2016). Staphylococcal vaccines, either S. 450 
aureus lysates or autogenous bacterin preparations have been assessed in small studies and warrant 451 
further investigations (Glos and Mueller, 2006). Antimicrobial peptides, which are produced by the 452 
skin and function as a vital part of cutaneous antimicrobial defence, are now being exploited in 453 
veterinary products for dogs. Two promising approaches have been adopted. In the first, plant 454 
extracts promoting production of endogenous antimicrobial peptides by the treated skin have been 455 
incorporated in shampoos and ear cleaners (Marsella et al, 2013; Santoro et al, 2016). In the second, 456 
a synthetic peptide (Cabassi et al, 2013) has been incorporated in shampoo, foam and an ear 457 
treatment gel. A variety of other approaches are being investigated and developed (Lloyd, 2012) but 458 
have not yet led to the development of veterinary products (Table 2). 459 
 460 
It is likely that at least some of these new approaches will prove successful, however we 461 
should not expect the development of agents which will allow us to ignore good drug stewardship 462 
and the adoption of rigorous hygiene. 463 
 464 
Conclusions 465 
Canine pyoderma will need to be managed appropriately to reduce morbidity and to limit 466 
the spread of potentially MDR pathogens amongst pets and humans. However, the availability of 467 
effective and safe systemic antimicrobials will become - or already is in some countries - 468 
substantially limited, either by continued selection of antimicrobial resistance amongst pathogens or 469 
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by legislative restrictions on prescribing by veterinary surgeons. We will likely need to adapt our 470 
prescribing practices for all animal species and all affected organs in the future. For canine 471 
pyoderma though, the skin as the infected organ can be easily accessed for examination and 472 
treatment monitoring, rapid in-house tests and topical therapy. This provides unique opportunities 473 
to combine relatively small achievable adaptations in our pyoderma management with good 474 
antimicrobial stewardship and effective treatment outcomes. Comprehensive owner education and 475 
rigorous hygiene measures need to become an integral part of pyoderma management and will help 476 
to limit the spread of antimicrobial resistance and delay the end the Golden Age of Antibiotics 477 
(Gould, 2009). 478 
 479 
Highlights 480 
1. Management of canine pyoderma is increasingly complicated by multidrug-resistant 481 
pathogens such as MRSP and empirical selection therapy is no longer reliable in areas with 482 
a high MRSP prevalence. 483 
2. Use of in-house cytology can rapidly confirm bacterial infection and support responsible 484 
antimicrobial prescribing. 485 
3. Topical therapy can be effective on its own in cases of superficial pyoderma, even in those 486 
involving MRSP. 487 
4. Awareness of risk factors, contagious and zoonotic characteristics, laboratory requirements 488 
and necessary hygiene measures are critical in the management of MRSP pyoderma. 489 
5. Diagnosis and treatment of underlying diseases needs to replace our reliance on 490 
antimicrobial therapy in dogs with recurrent pyoderma. 491 
 492 
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Table 1 1046 
The changing nomenclature of Staphylococcus aureus. 1047 
 1048 
Name Year Comments 
Staphylococcus pyogenes aureus 1886 (Rosenbach) Representing golden (rather than white) 
staphylococcal colonies 
S. aureus 1951 (Shaw et al.) Representing all coagulase positive 
staphylococci 
Methicillin-resistant S. aureus (MRSA) 1961 (Jevons) First recognition of methicillin resistance in S. 
aureus 
S. aureus 1971 (Hajek and Marsálek) Differentiation of animal species-related 
biotypes A-F 
S. intermedius 1976 (Hajek) Differentiated from S. aureus, representing 
biotypes E and F 
S.pseudintermedius 2005 (Devriese et al.) Differentiated from S. intermedius, representing 
biotype E.  
Staphylococcus intermedius group (SIG) 2007 (Sasaki et al.) Includes S. intermedius, S. pseudintermedius 
and S. delphini which are difficult to 
differentiate in routine laboratory testing. S. 
intermedius shown to be mainly associated with 
wild pigeons.* 
Methicillin-resistant S. pseudintermedius 
(MRSP) 
2007 (Sasaki et al.) First recognition of methicillin resistance in S. 
pseudintermedius 
 1049 
*Canine SIG isolates are always considered as S. pseudintermedius (Bannoehr et al., 2007).  1050 
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Table 2 1051 
New and alternative antimicrobial approaches. 1052 
 1053 
Approach Action 
Efflux pump inhibitors Suppress elimination of antimicrobial agents 
Silencing of resistance and virulence genes Antagonise function of specific genes 
Quorum quenching Agents suppressing virulence of pathogen 
Probiotics and prebiotics Provide or promote competitor bacteria 
Microbial predation Bacterial or fungal predators consume pathogen 
Bacteriophages  Invade and destroy pathogen 
Vaccines and immunoglobulins Stimulate or passively provide immunity 
 1054 
  1055 
 34 
Figure legend 1056 
 1057 
Fig. 1. Examples of recurrent or chronic (> 3 months) pyoderma involving multidrug-resistant 1058 
bacteria. All cases had received repeated courses of systemic antimicrobials with initial 1059 
improvement. Pyoderma resolved when underlying triggering causes were diagnosed and treated in 1060 
combination with antibacterial therapy. (A) Acute moist dermatitis with methicillin-resistant 1061 
Staphylococcus pseudintermedius (MRSP) on the neck of a young atopic Saint Bernard. (B) 1062 
Purulent Klebsiella spp. infection complicating erosive pad lesions in a sterile granulomatous 1063 
disease. Both dogs were treated and remained in remission with topical antibacterial and systemic 1064 
anti-inflammatory treatment. (C) Recurrent superficial pyoderma with expanding epidermal 1065 
collarettes and focal crusts due to MRSA in a dog with early hyperadrenocorticism; infection 1066 
resolved with topical antibacterial washes alone when the endocrinopathy was treated. (D) 1067 
Widespread deep pyoderma involving Pseudomonas aeruginosa in a young Dalmatian dog with 1068 
juvenile-onset demodicosis; there was no evidence of pyoderma on cytology after 3 weeks of 1069 
systemic antibacterial and acaricidal therapy. 1070 
  1071 
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